Loading
Total declarations
Companies
▲ Purchases (8 ops.)
▼ Sales (2 ops.)
Latest filing published 05 Aug 2026 for PFIZER INC, €866k.
Filing timeline
BuySaleRonald E. Blaylock
Insider track record
Disclosed buys
8
Disclosed sells
2
Signal history
Closed purchases
Market purchases
8
Positive at T+90
86%
Median T+90
+3.7%
Based on 7 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +12.9%Entry US$26.20 · Close 16 Oct 2026 US$29.58
- +7.1%Entry US$25.56 · Close at T+365 US$27.37
- +29.2%Entry US$35.85 · Close at T+365 US$46.31
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Ronald E. Blaylock: trading record in brief
Ronald E. Blaylock is a Director at 5 US companies, and purchases outweigh sales in the filings: 8 purchases against 2 sales, which is 80% of the market trades. The purchases, almost all at Pfizer Inc, total EUR 1.8 million, median EUR 89,273. The largest are EUR 866,178 on August 5, 2026, EUR 480,247 on February 13, 2025 and EUR 129,634 on August 6, 2020.
The 2 sales took place at Carmax Inc: EUR 1,397,118 on July 16, 2021 and EUR 803,468 on July 13, 2020, EUR 2.2 million in all. There are also 25 grants.
The record gathers 38 filings published from May 26, 2016 to August 5, 2026: Berkley W R Corp (13), Carmax Inc (11), Pfizer Inc (10), Advantage Solutions Inc. (3) and Urban One, Inc. (1). 2020 has 11 of them, against 2 to 7 in the other years. Two filings fall in the last twelve months, one of them a purchase.
Trades by Blaylock within 30 days of colleagues number 2, 2 and 2. Every one in the same direction. Names in order: Charles Joseph Wilson (Carmax Inc), Diane L. Cafritz (Carmax Inc) and Edwin J. Hill (Carmax Inc). Publication takes place a median of 3 days after the trade.
Companies and markets linked to Ronald E. Blaylock
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations38 total
39,231 shares@ US$25.460.0006% mcap64.3% of flowCommon StockSEC:0001225208-26-006944:0
Canonical exit: 3 Nov 2026 (T+90)
3,090 shares0Common StockSEC:0001193125-26-257637:0
2,776 shares0Common StockSEC:0001062993-25-011678:0
19,457 shares@ US$25.6535.7% of flowCommon StockSEC:0001225208-25-001778:0
Canonical exit: 14 May 2025 (T+90)
2,598 shares0Common StockSEC:0001170010-24-000112:0
2,534 shares0Common StockSEC:0001062993-24-012472:0
2,210 shares0Common StockSEC:0001170010-23-000082:0
3,479 shares0Common StockSEC:0001062993-23-013562:0
1,996 shares0Common StockSEC:0001170010-22-000081:0
2,995 shares0Common StockSEC:0001062993-22-014902:0
40,603 shares0Class A Common StockSEC:0000947871-22-000665:0
12,500 shares@ US$132.02100.0% of flowCommon StockSEC:0001170010-21-000166:0
1,308 shares0Common StockSEC:0001170010-21-000154:0
4,750 shares0Common StockSEC:0001225208-21-010304:1
4,750 shares0Common StockSEC:0001225208-21-010304:0
2,652 shares0Common StockSEC:0000011544-21-000032:0
14,344 shares0Class A Common StockSEC:0000947871-21-000650:0
10,356 shares0Class A Common StockSEC:0000947871-21-000028:0
4,000 shares@ US$38.497.3% of flowCommon StockSEC:0001225208-20-010436:0
Canonical exit: 4 Nov 2020 (T+90)
3,000 shares@ US$38.555.5% of flowCommon StockSEC:0001225208-20-010436:1
Canonical exit: 4 Nov 2020 (T+90)
2,500 shares@ US$38.564.6% of flowCommon StockSEC:0001225208-20-010436:2
Canonical exit: 4 Nov 2020 (T+90)
1,500 shares@ US$38.512.8% of flowCommon StockSEC:0001225208-20-010436:3
Canonical exit: 4 Nov 2020 (T+90)
1,000 shares@ US$38.691.8% of flowCommon StockSEC:0001225208-20-010436:4
Canonical exit: 4 Nov 2020 (T+90)
1,000 shares@ US$38.621.8% of flowCommon StockSEC:0001225208-20-010436:5
Canonical exit: 4 Nov 2020 (T+90)
10,200 shares@ US$89.3736.5% of flowCommon StockSEC:0001170010-20-000136:0
25 of 38 declarations
